Private companies have begun offering services to allow parents undergoing in-vitro fertilisation to screen embryos for genetic risk of complex diseases, including psychiatric disorders. This procedure, called polygenic embryo screening, raises several difficult scientific and ethical issues, as discussed in this Personal View. Polygenic embryo screening depends on the statistical properties of polygenic risk scores, which are complex and not well studied in the context of this proposed clinical application. The clinical, social, and ethical implications of polygenic embryo screening have barely been discussed among relevant stakeholders. To our knowledge, the International Society of Psychiatric Genetics is the first professional biomedical organisation to issue a statement regarding polygenic embryo screening. For the reasons discussed in this Personal View, the Society urges caution and calls for additional research and oversight on the use of polygenic embryo screening.

私营公司已开始提供服务，允许接受体外受精的父母筛选胚胎中复杂疾病（包括精神疾病）的遗传风险。正如本个人观点中所讨论的，这一过程称为多基因胚胎筛查，它提出了一些困难的科学和伦理问题。多基因胚胎筛查取决于多基因风险评分的统计特性，这些特性很复杂，并且在本提议的临床应用背景下尚未得到充分研究。相关利益相关者之间几乎没有讨论多基因胚胎筛查的临床、社会和伦理影响。据我们所知，国际精神病遗传学学会是第一个就多基因胚胎筛查发表声明的专业生物医学组织。由于本个人观点中讨论的原因，协会敦促谨慎行事，并呼吁对多基因胚胎筛查的使用进行更多研究和监督。